Concepedia

Adam Shutes

AS

18

Publications

1.8K

Citations

16

H-Index

1998

Active since

Affiliations

University of North Carolina at Chapel Hill(Current)

Blueprint Medicines (United States)

Ono Pharmaceutical (United States)

Merck Serono (Italy)

Merck (Germany)

Adam Shutes is an author at University of North Carolina at Chapel Hill specializing in medicine, molecular biology, and drug discovery.

Top concepts

Publications per year

1998–2019

18

Publications

18

Specificity and Mechanism of Action of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases

Adam Shutes, Cercina Onesto, Virginie Picard et al. · Journal of Biological Chemistry · 2007 · 336 citations · Full text

, , +17

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Margit Hagel, Chandra Miduturu, Michael P. Sheets et al. · Cancer Discovery · 2015 · 305 citations · Full text

A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutations

Erica N Evans, Alexandra K. Gardino, Joseph L. Kim et al. · Science Translational Medicine · 2017 · 209 citations

The p85 Subunit of Phosphatidylinositol 3-Kinase Associates with the Fc Receptor γ-Chain and Linker for Activitor of T Cells (LAT) in Platelets Stimulated by Collagen and Convulxin

Jonathan M. Gibbins, Stephen J. Briddon, Adam Shutes et al. · Journal of Biological Chemistry · 1998 · 145 citations · Full text

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

Richard D. Caldwell, Hui Qiu, Ben Askew et al. · Journal of Medicinal Chemistry · 2019 · 136 citations · Full text

, , +14

Rows per page

1–5 of 18